Many patients with chronic heart failure experience reduced health status despite receiving conventional therapy.
M any of the 5.8 million Americans with heart failure live with bothersome symptoms, reduced function, and poor quality of life, which together comprise health status. For example, common symptoms reported by patients with heart failure include breathlessness (44%-85%), fatigue (66%-85%), pain (38%-58%), and depression (19%-55%). [1] [2] [3] This morbidity occurs regardless of left ventricular ejection fraction and despite the use of guidelinedirected therapies. Patient-reported health status is important because it reflects the patient's experience of illness and is associated with subsequent hospitalization and mortality. 4 Interventions that improve the health status of patients with heart failure are needed. Depression is associated with heart failure-specific health status, 5 and combining treatment of depression with palliative management of persistent, burdensome symptoms of heart failure could improve health status. 6, 7 Palliative care for patients with heart failure is recommended by professional societies, the National Academy of Medicine, and the World Health Organization, [8] [9] [10] and palliative care provided by specialists shows promise in improving the health status of patients with heart failure. [11] [12] [13] [14] Existing studies have largely examined the role of palliative care among patients hospitalized with heart failure; however, many outpatients with heart failure report reduced health status. 4 Despite the promise of palliative care for heart failure, there are not enough palliative care specialists to treat all patients with heart failure and reduced health status. Furthermore, interventions to improve the health status of patients with heart failure are unlikely to be successful unless they can be integrated earlier in the course of the illness into ongoing outpatient heart failure care and be scalable to the large numbers of patients with reduced health status.
To address these challenges, the Collaborative Care to Alleviate Symptoms and Adjust to Illness (CASA) intervention was developed. 15 The CASA intervention uses a collaborative care health care delivery model to improve health status by concomitantly addressing persistent bothersome symptoms, adjustment to illness, and depression. 6, 7 To increase scalability, the CASA health delivery model leverages nurses and social workers to provide telephonic care of symptoms and depression. By combining palliative approaches to symptoms with psychosocial care for depression, we hypothesized that the CASA intervention would improve the health status of outpatients with heart failure. The multisite CASA trial evaluated the effect of the CASA intervention on the primary outcome of heart failurespecific health status in a population of patients with poor health status. Secondary outcomes included common symptoms (fatigue, pain, shortness of breath, anxiety, and depression), hospitalizations, and mortality.
Methods

Study Design
The CASA trial was a National Institutes of Health-funded single-blind, 2-arm, randomized clinical trial that compared the CASA intervention with usual care in 3 health systems (urban safety net, Veterans Affairs, and academically affiliated health systems). This article reports the primary outcome and main secondary outcomes previously described in the study conceptual model. 7 The methods have been previously reported. 7 The study protocol in the Supplement was approved by the Colorado Multiple institutional review board, and the trial was regularly reviewed by an independent data and safety monitoring committee. Patients provided written informed consent.
Population
The eligibility criteria aimed to enroll patients with chronic heart failure and reduced health status who were likely to need the additional resources provided by the intervention. Patients with heart failure were identified through the study sites' electronic health records. The diagnosis was defined using previously validated administrative data 16 supplemented with data on required diuretic dosing (furosemide ≥80 mg/d or equivalent), left ventricular ejection fraction of 40% or less, braintype natriuretic peptide (BNP) levels of 250 pg/mL or more (to convert to nanograms per liter, multiply by 1.0), or Nterminal prohormone level of BNP of 1000 pg/mL or more. During the study screening process, patients who reported reduced heart failure-specific health status (a Kansas City Cardiomyopathy Questionnaire Short Version 17 [KCCQ] score of ≤70) or reported at least 1 of the study's target symptoms (fatigue, shortness of breath, pain, and/or depression) were targeted for enrollment. Patients with active substance abuse or serious mental illness were excluded. Receipt of guidelineindicated therapy was not an eligibility criterion. Early in the study, the cutoffs for diuretic dosing and BNP were relaxed (furosemide level of ≥20 mg/d, BNP level of ≥100 pg/mL, or Nterminal prohormone level of BNP of ≥500 pg/mL), and both reduced heart failure-specific health status and 1 of the target symptoms were required to increase the eligible study population while still enrolling symptomatic patients. Eligible patients who provided informed consent completed baseline measures and were then randomized to receive the CASA intervention or usual care. The randomization sequence was computer-generated using random block sizes and stratification by study site and was concealed from study personnel. Randomization occurred between August 2012 and April 2015, and ended when the goal sample size was accrued. All participants were compensated $10 to $15 at each data collection time point.
CASA Intervention
The CASA intervention included 3 components. A registered nurse addressed symptoms, a social worker provided structured psychosocial care, and a team (including the nurse and social worker, a primary care clinician [C.F.M.], palliative care specialist [D.B.B.], and cardiologist [B.H.]) reviewed patients' care and provided orders for tests and medications to patients' clinicians for review and signature. The registered nurse and social worker were trained to provide the CASA intervention; they were not specialist palliative care clinicians.
The patient and nurse selected an initial symptom on which to focus from a choice of pain, breathlessness, fatigue, or depression. 7 These symptoms were chosen because most patients with heart failure experience at least 1 of these symptoms as burdensome and because each symptom is associated with patient-reported health status. 2, 3 The nurse assessed and managed symptoms using structured guidelines developed for the study, including disease-specific, behavioral, and palliative approaches. 7 Additional symptoms, including those beyond the symptoms with structured guidelines, were revisited later during the intervention if needed. The nurse was trained in helping communication (1 hour), motivational interviewing (4 hours), and the symptom guidelines (3 hours).
Six nurse intervention follow-up assessments by telephone (1-2 per month) were planned using a structured symptom rating scale. The symptom rating scale assessed severity, burden, and management capability of pain, shortness of breath, and fatigue using a 10-point Likert scale. It also assessed depression and anxiety using the 4-item Patient Health Questionnaire. 18 These data were used by the intervention team for ongoing management of symptoms that were not improving. The nurse applied motivational interviewing to promote changes in health behaviors (eg, medication adherence, diet, and physical activities) that could improve patient symptoms. 19 The nurse had access to a PhD-level clinical nurse specialist to discuss difficult issues regarding symptom management. The social worker provided a structured telephonebased psychosocial intervention to help patients with heart failure adjust to living with illness and address depression symptoms, if present. 20 The psychosocial intervention was operationalized in a treatment manual and was based on interpersonal and behavioral activation psychotherapies. 21, 22 The following topics were included in approximately 6 counseling sessions (each of which could be split over multiple visits): grief and loss, change in role, behavioral activation, and pacing. The social worker also provided support to patients' informal caregivers as needed. The social worker received 8 hours of psychosocial intervention training and follow-up supervision. The nurse and the social worker discussed the patients in weekly collaborative care team meetings with a primary care clinician, a cardiologist, and a palliative care physician. This team was part of the CASA intervention and not part of usual care ( Table 1 illustrates how CASA differs from usual care) because patients' current care clinicians could not feasibly participate in team meetings. The collaborative care team was used because this model of care is scalable and effective in improving depression and other symptoms in medically ill patients. [23] [24] [25] Based on review of patients' medical records and discussion with the nurse and social worker, the team recommended medications and tests (and wrote orders for them when feasible at the site) for the patients' usual care clinicians to review and give final approval. The nurse communicated with patients and their clinicians to follow up on these recommendations. A single intervention team provided care for patients in 3 different health systems.
Usual Care
Patients in the usual care group received care at the discretion of their clinicians, which could include care from cardiology, palliative care, and mental health (Table 1 ). Patients were also given an information sheet developed for the study that outlined selfcare for heart failure. Finally, patients in the usual care arm who had significant depressive symptoms were notified of this, and their clinicians were also contacted. Referring clinicians then assumed responsibility for depression care at their discretion, with no constraints on treatment or referrals.
Outcomes
Patient-reported measures included the KCCQ (primary outcome), a valid, reliable measure of heart failure-specific health status that is responsive to change. 26, 27 The scale range is from 0 to 100; lower scores indicate poorer health status, and a change of 5 is thought to be a clinically meaningful difference. Many patients already had cardiologists.
Telephone and between-visit care
Core to the intervention; most visits were by telephone.
Ad hoc.
Abbreviation: CASA, Collaborative Care to Alleviate Symptoms and Adjust to Illness.
The 9-item Patient Health Questionnaire measured depression (range, 0-27; higher indicates more depressive symptoms). [28] [29] [30] The single-item General Symptom Distress Scale measured overall symptom distress (range 0-10; higher score indicates more distress). 31 The PEG (3 items, derived from the Brief Pain Inventory) measured pain intensity (P), interference with enjoyment of life (E), and interference with general activity (G) (range, 0-30; higher score indicates more pain). 32 We assessed shortness of breath using the same response items as the PEG. The Patient-Reported Outcomes Measurement Information System Short Form 8a measured fatigue (range, 0-48; higher score indicates more fatigue). We added the 7-item Generalized Anxiety Disorder to measure anxiety as an exploratory outcome. 33 Measures were completed in person, by mail, or by telephone at baseline and at 3, 6, and 12 months by personnel who did not provide the intervention and were unaware of treatment arm assignment and intervention activities. Hospitalizations and all-cause mortality were assessed by data in the medical records in each health system, supplemented with patient or family self-report. Hospitalizations and mortality were reported (blinded) during the study to the data and safety monitoring committee.
Sample Size
The primary study hypothesis was that patients receiving the CASA intervention would show greater improvement in heart failure-specific health status at 6 months compared with those receiving usual care. We planned a sample size of 312 to detect a change in KCCQ score of 6 to 8 points, greater than the clinically meaningful 5-point difference. 26 We anticipated a 25% dropout rate owing to death and other reasons. As the SD for the KCCQ has ranged from 15 to 20 in prior studies, with this sample size, we had 86% power to detect a change of 6 points (assuming an SD of 15) or 8 points (assuming an SD of 20) (2-sided test, α = .05).
Statistical Analysis
Data from all participants were included regardless of the level of participation, using an intent-to-treat approach. Baseline characteristics of patients were assessed by study group using 34 The number of allcause hospitalizations and deaths was compared between study arms using the Mantel-Haenszel χ 2 test. P < .05 was considered significant.
Results
Of 317 patients randomized, 3 failed screening; thus, 314 were included in the intent-to-treat analysis (Figure) . Baseline characteristics were balanced between groups, except those in the intervention group were significantly more likely to have a biventricular pacemaker and to be less short of breath compared with those in the control group ( (Figure) .
In the intervention arm, 106 of 157 patients (67.5%) chose fatigue or breathlessness as an initial symptom of focus, 29 (18.5%) chose pain, and 17 (10.8%) chose depression ( Table 3 The primary outcome of difference in change scores on the KCCQ at 6 months did not differ significantly between groups: the mean KCCQ score improved 5.5 points in the intervention arm and 2.9 points in the control arm (difference, 2.6; 95% CI, -1.3 to 6.6; P = .19) ( Table 4) . Intervention effect on KCCQ differed by site (site 1 [n = 191]: effect size, 0.10; site 2 [n = 84]: effect size, 0.07; site 3 [n = 42]: effect size, 0.60) and ejection fraction (heart failure with reduced ejection fraction: effect size, 0.28; heart failure with preserved ejection fraction: effect size, -0.03). Among secondary outcomes, depressive symptoms improved with CASA (the effect size was -0.34 at 3 months [P = .01] and -0.29 at 6 months [P = .02]). This effect persisted at 12 months (effect size, -0.36; P = .006). Fatigue also improved with CASA at 6 months (effect size, -0.30; P = .02), yet this change did not persist at 12 months (effect size, -0.18; P = .16). Anxiety improved with CASA at 3 months (effect size, -0.28; P < .001), although the improvement at 6 months did not reach statistical significance (effect size, -0.21; P = .09). There were no changes in overall symptom distress, pain, or shortness of breath. Mortality at 12 months was similar in both arms (10 of 157 patients died receiving CASA, and 13 of 157 patients died receiving usual care; P = .52). The distribution of the number of hospitalizations among patients was not statistically different between arms (CASA, 18 patients with 1 hospitalization and 9 with ≥2 hospitalizations; usual care, 30 patients with 1 hospitalization and 6 with ≥2 hospitalizations; P = .61). There were no harmful adverse events attributed to the intervention.
Discussion
To our knowledge, the CASA trial is the first clinical trial of a palliative and psychosocial collaborative care intervention for patients with heart failure. Study strengths included the relatively large number of patients with heart failure and reduced health status, the diverse patient population enrolled from disparate health systems, and the use of a central team that provided care to patients at the 3 health systems. In this multisite trial of 314 patients with heart failure and reduced health status, the CASA intervention did not demonstrate improved overall heart failure-specific health status compared with usual care. Among secondary outcomes, depressive symptoms and fatigue improved with the intervention at 6 months (anxiety improved at 3 months), while overall symptom distress, pain, and shortness of breath did not improve.
Several reasons could account for the lack of intervention effect on heart failure-specific health status. The intervention may not have been of adequate intensity. Although the rate of medical order completion was high, it was less than 100%, which may have diminished the intervention effect. The heart failure-specific health status measure, the KCCQ, is weighted toward symptoms and function and may not have captured the effect demonstrated by other palliative care interventions on measures weighted more toward the social, family, and emotional components of quality of life. 35, 36 The cohort, while demonstrating significantly reduced baseline health status, had relatively low rates of death and hospitalization compared with large ambulatory cohorts of patients with heart failure. This difference may have limited modifiable heart failure-related contributors that could be affected by the intervention. The baseline KCCQ score was lower in the control arm, which may have led to more regression to the mean, limiting e Depression was measured using the PHQ-9; a score of 10 or higher is considered a positive screening result for depression.
f Anxiety was measured using the Generalized Anxiety Disorder Questionnaire-7; a score of 10 or higher is considered a positive screening result for anxiety.
g Lack of energy, shortness of breath, and pain measured using single items from the Memorial Symptom Assessment Scale; percentage of participants reporting the symptom "quite a bit" or "very much bothersome." P = .005 for difference in proportion of those with bothersome shortness of breath. a Breathlessness and fatigue were combined, as they had similar assessments.
our ability to detect an intervention effect. Finally, it is possible that the study was underpowered to detect a more modest intervention effect. The improvement in depression without improvement in heart failure-specific health status raises questions about the relationship between these 2 facets of the patient experience. Longitudinal studies demonstrate that depression and heart failure-specific health status are connected in patients with heart failure 5 ; however, in both this trial and a previous trial, 37 improvements in depression were not associated with improvements in heart failure-specific health status, a key component of the study conceptual model. The link between depression and quality of life outcomes is strongest in randomized clinical trials that enroll only patients with depression. 24, 38 This link should be considered in future study designs. Depression and fatigue, both secondary outcomes, improved with the CASA intervention. Anxiety also improved at 3 months, yet this effect did not reach statistical significance at 6 months. Limited treatments exist for these common, bothersome symptoms in patients with heart failure. [39] [40] [41] [42] For example, 2 randomized clinical trials of serotonin-specific reuptake inhibitors failed to show improved depressive symptoms in patients with heart failure. 39, 40 The effect of the CASA intervention on depressive symptoms is at the upper end of effect sizes described in a meta-analysis of 37 collaborative care trials for primary care patients with depression (mean effect size, 0.025; 95% CI, 0.18-0.32). 23 These findings should be considered in the context of the CASA study population, which included patients with varying degrees of severity of depressive symptoms (half the patients screened positive for depressive disorder and 23% had depressive disorder, according to the 9-item Patient Health Questionnaire). The effect on depressive symptoms persisted at 12 months, which, for many patients, was 9 months after the intervention completed. b Heart failure-specific health status score range is from 0 to 100; a higher number means better health status.
c Depressive symptom scores range from 0 to 27; a higher number means more depressive symptoms.
d Anxiety symptom score range from 0 to 21; a higher number means more anxiety symptoms.
e Symptom distress scores range from 0 to 10; a higher number means more overall distress from symptoms.
f Pain scores range from 0 to 10; a higher number means more pain.
g Fatigue scores range from 0 to 32; a higher number means more fatigue.
h Dyspnea scores range from 0 to 10; a higher number means more shortness of breath. The CASA trial studied a structured, scalable intervention that could be integrated into outpatient care and could be provided earlier in the course of the illness prior to the end of life by nurses and social workers who collaborated with physicians. The CASA intervention differed from heart failure disease management and palliative care interventions by implementing a structured, manualized psychosocial care protocol, using a collaborative care model and structured guidelines to address common burdensome symptoms chosen by patients. The next steps in research could include (1) testing intervention components on specific outcomes (eg, psychosocial care intervention for patients with depressive disorder or fatigue); (2) studying the intervention in a higher-risk or more ill population, as another study using specialist palliative care has done, 11 or an underserved or rural population; and (3) using health information technology (eg, videoconference) to increase the reach, intensity, or scalability of the intervention. It is possible that further refinement of the intervention could improve disease-specific health status.
Limitations
The generalizability of the study findings may be limited because recruitment occurred in 1 US region and because the study population had a high proportion of men. Because of the nature of the intervention, participants could not be blinded.
The missing patient-reported data rate of 21% at 6 months, equivalent in both arms, is similar to other studies of seriously ill populations. 11,36,38 Because we did not use an attention control group or measure usual care clinician time spent with patients, we cannot infer that the improvements in depression and fatigue were related to specific components of the intervention rather than nonspecific benefits from clinician attention or participation in the psychosocial intervention. Finally, there is a chance that specialist palliative care consultation in the usual care arm may have improved outcomes in the usual care group.
Conclusions
This multisite randomized clinical trial of the CASA intervention did not demonstrate improved heart failure-specific health status. Secondary outcomes of depression and fatigue, both difficult symptoms to treat in heart failure, improved. Further research is needed to test scalable models of outpatient palliative care in heart failure to improve patient outcomes. Role of the Funder/Sponsor: The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Disclaimer:
The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the National Institutes of Health, the Department of Veterans Affairs, or the United States government. Overall goal: To study the effectiveness of a symptom management and psychosocial care intervention, Collaborative Care to Alleviate Symptoms and Adjust to Illness (CASA), in patients with chronic heart failure (CHF) at the Denver VA Medical Center, Denver Health, and University of Colorado Hospital. This is a study of behavioral and care strategy interventions and involves no investigational drugs or devices.
Specific Aims: Aim 1. Assess the effect of a symptom management and psychosocial care intervention on heart failurespecific health status as a primary endpoint, and symptom distress, depression, quality of life, self-care, and spiritual well-being as pre-specified secondary endpoints.
Aim 2. Evaluate whether the intervention influences quality of life indirectly through effects on symptom distress and depression.
Aim 3. Examine the effect of the intervention on informal family caregivers' depression, burden, benefit-finding, social support, perceptions of patients' symptoms, quality of the patient-caregiver relationship, and contributions to patients' heart failure self-care.
Aim 4. Identify valuable core CASA intervention content and processes from the perspectives of patients and intervention team members.
Aim 5. Identify barriers and facilitators to the implementation and sustainability of CASA from the perspectives of providers (i.e., physicians, nurse practitioners) whose patients received the CASA intervention.
Aim 6. Determine interest and capacity of rural clinic settings to adopt CASA's team-based model of outpatient palliative and psychosocial care.
Background and Significance:
Symptom severity in HF prompts health care utilization, 1-3 independently predicts hospitalizations and mortality, 4 and contributes substantially to the high cost of HF care. 5 Furthermore, symptoms increase suffering and reduce quality of life in patients with HF 6 Many patients report the typical HF symptoms of breathlessness (44-85%) and fatigue (66-85%) as well as depression (19-55%), pain (38-58%), and other symptoms that reduce quality of life and persist over time [7] [8] [9] A mean of 15 physical and emotional symptoms are experienced concurrently. 6, 7 Previous HF intervention studies do not measure or improve the large number of symptoms HF patients' experience. 10, 11 Studies focus on treating disease and evaluating hospitalization and mortality outcomes, acute changes in breathlessness with diuretics, and occasionally health status. Furthermore, major trials of telemonitoring 12 , disease management, 13 and education 14 have not shown significant improvement in patientcentered outcomes such as symptoms, in part because they are heavily focused on volume management.
Prior palliative care interventions to improve symptoms and quality of life in outpatients with HF are sparse, have mixed results, and did not use high quality randomized study designs. [15] [16] [17] Symptoms worsened in the intervention arm of one trial, 16 and in another, common symptoms including depression and pain did not improve. 15 These previous palliative symptom management interventions did not include effective depression or psychosocial care, although it is known that depression increases the intensity of other symptoms. 6, 18, 19 Our proposed study addresses key gaps in the fields of HF, palliative care, and nursing research.
Our study design will further contribute to the design of HF palliative care interventions focused on improving quality of life by examining the relative impact of different predictors of quality of life. While symptoms are strongly related to quality of life in cross-sectional studies, the relative importance of symptoms compared to Previous HF intervention studies do not measure or improve the large number of symptoms HF patients' experience, and prior palliative care interventions were unsuccessful, in part because of inadequate psychosocial care. We will test the hypothesis that an innovative, evidence-based, theory-driven symptom management and psychosocial care intervention will reduce symptom severity and depression in intervention patients compared to patients receiving usual care. We will test this hypothesis using a 3-site, 2-arm randomized, controlled trial (RCT) with outcome assessments at baseline, 3, 6, and 12 months in participants with a primary hospital diagnosis of HF that is advanced. The effect of the intervention on overall symptom severity and depression will be examined using linear mixed-effect models. The rationale for this aim is that if the intervention is successful, the research will contribute a patient-centered intervention that can be replicated, implemented, and disseminated in diverse health systems.
We plan to assess the effect of a symptom management and psychosocial care intervention on heart failure-specific health status as a primary endpoint. The study conceptual model and the proposed intervention effects are illustrated in Figure 1 . The conceptual model is based on integrating elements of Lenz' unpleasant symptom theory 20 into an adaptation of the Wilson and Cleary model of health related quality of life. 21 Antecedent factors, the symptom experience, and depression/anxiety influence health-related quality of life. Heart failure-specific health status and spiritual well-being 22 have been conceptualized as components of quality of life.
Additionally, we plan to include and assess the role of informal family caregivers in our intervention. Evidence suggests that relationships heart failure patients have with their caregivers can influence patients' self-care, 23 fatal and non-fatal cardiac events, 24 and survival, 25 where better relationships predict more favorable outcomes and poor relationships predict adverse outcomes. Moreover caregivers' feelings of burden and depression are negatively related to patients' perceptions of relationship quality and self-care, 26 which may influence patient outcomes. There is little understanding of how caregivers influence patient outcomes, and this study will examine the role of caregivers in a symptom management intervention.
Briefly, the intervention is a palliative symptom management and psychosocial care (PSMPC) intervention that includes (a) evidence-based palliative symptom management of breathlessness, fatigue, and pain, provided by a nurse; (2) a 6-8 session structured psychosocial care protocol targeting depression and adjustment to illness, supplemented by informal (family) caregiver assessment and support, provided by a social worker or psychologist; and (3) brief weekly team meetings with the nurse, social worker/psychologist and a palliative care specialist, cardiologist, and primary care provider.
Preliminary Studies:
The study team has led multiple projects in HF palliative care that support the proposed conceptual model (Figure 1) and components of the palliative symptom management and psychosocial care intervention. 6, [27] [28] [29] [30] [31] Several studies demonstrated that depression and symptom experience must both be addressed to improve health-related quality of life as they are highly interrelated and are key contributors to quality of life. 6, 27 In a qualitative study of patients with HF and their informal caregivers, participants reported that they desire symptom alleviation and psychosocial support early in illness, integrated with disease-specific care, and coordinated by a provider who understands their heart condition and knows them well. 31 Each component of the palliative symptom management and psychosocial care intervention and their combination has proven feasible.
(1) The PI, Dr. Bekelman, served as the site investigator at the Denver VA Medical Center for a multi-site HF disease management RCT that successfully recruited an average of 8 HF patients per month and implemented a team-based care delivery approach in HF patients (VA HSR&D CCN 06-068-3/COMIRB #07-0588; Rumsfeld, PI, Bekelman, Co-I). Both this study and the VA Collaborative Cardiovascular Care (C3P) trial (HSR&D IHI 02-062-1) 32 employed team-based collaborative care successfully. For example, in the C3P study (Hattler, Co-I), 90% of medication recommendations written by the collaborative care team were implemented by primary care providers. (4) The combination of these components has been tested in our pilot study designed to test the feasibility of palliative symptom management and psychosocial care intervention (PSMPC). In our initial piloting, we randomized patients to receive PSMPC, a mail-based psychospiritual intervention, or both. Patients at the VA were overwhelmed with both interventions and therefore we changed the randomization to be one intervention compared to the other. We found that both interventions could be feasibility implemented at the VA. We expanded our recruitment to Denver Health and University of Colorado Hospital and have tested the feasibility of the PSMPC intervention at these other two sites.
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Experimental Design and Methods:
Study Design:
The study design is being modified based on findings from initial pilot testing and receipt of funding for a multisite efficacy trial (1R01NR013422-01, Bekelman, PI The study is a 3-site, 2 arm randomized controlled trial of the PSMPC intervention vs. usual care control.
Study Sites: The Denver VA Medical Center, the University of Colorado Hospital, and Denver Heath Study Duration: Four years.
Study Population: We will recruit patients (n=400; 45 for initial pilot testing and 355 effectiveness trial screening, with a goal of enrolling 312 patients into the RCT) with CHF who meet the eligibility criteria described in Table 1 . The eligibility criteria were chosen so that participants are likely to be symptomatic and have a poor quality of life, both of which are targeted with the interventions. The eligibility criteria define a cohort with chronic disease (previous HF diagnosis) that is symptomatic based ONE OR MORE of five previously established criteria: previous hospitalization for HF, 34, 35 high diuretic use, 36 high BNP, 37 low ejection fraction and low Kansas City Cardiomyopathy (KCCQ, a self-report measure of HF health status, see "Measures") score. 38 The rationale for enrolling patients age 18 years or older who are able to read and understand English is that the intervention was developed in English for adults and the majority of the study instruments have been validated only in English. VA patients need to have a primary care provider within the Eastern Colorado Health Care System (ECHCS) so that orders and consults can be made within the medical record that the primary care provider (PCP) can sign. Subjects who have a previous diagnosis of dementia will be excluded because the intervention requires participation in counseling that was not developed for people with dementia, and most of the questionnaires were not validated in persons with dementia. Subjects who have problems with active substance abuse, defined as an AUDIT-C score ≥ 8 39 , a diagnosis of substance abuse or dependence or positive response on a substance abuse screening question, are unlikely to participate in the regular follow up phone calls or respond to the intervention and will be excluded. Subjects with comorbid metastatic cancer are excluded because this study focuses on heart failure rather than cancer palliative care. Additionally, patients with diagnoses of bipolar affective disorder or schizophrenia will be excluded because the counseling components of the intervention were not designed for these patient populations. Patient who have received heart transplants or left ventricular assist devices (LVAD) will be excluded because their care is heavily focused on post-transplant and LVAD management and they rarely see their primary care providers, making it difficult to implement this intervention. Finally, nursing home residents, except those undergoing rehabilitation in the VA Community Living Center, will be excluded since this study is focused on outpatient care. Competence for study participation will be evaluated by potential participants' ability to explain to study personnel the goals of the study, requirements of study participation, and potential risks and benefits.
Enrolled patients (n=312) will be asked to identify an informal (family) caregiver 18 years of age or older who is "the one person (besides a health care provider) who helps you the most with your medical conditions." Informal caregivers must be at least 18 years of age, able to read or understand English, and not be a paid caregiver. If the informal caregiver is interested in participation and provides informed consent, they will also participate in the study (Aim 3).
We will conduct brief (15min) interviews with patients that participated in the intervention to get their feedback on the effectiveness of the intervention. We will also host focus groups with intervention staff to discuss effectiveness of intervention (Aim 4). There will be separate focus groups for physician and non-physician intervention staff to reduce power differentials between physician and non-physician personnel.
Providers (i.e., physicians, nurse practitioners) that have had patients participate in the intervention will be asked to complete a brief survey regarding their perspective on the usefulness of the CASA intervention and how it might be implemented in actual clinical practice (Aim 5). This will be done after their patients complete the intervention. We anticipate sending surveys to up to 100 care providers.
We will also explore potential implementation of CASA in rural areas (Aim 6). We will perform site visits to rural clinics to meet with up to 20 health care leaders and providers. We will use structured interviews and survey data to explore challenges unique to rural areas, such as resource scarcity (personnel, technological, etc.). This phase of the project will begin Spring 2015 so as to incorporate what we have learned from patient, staff and care provider qualitative data.
Recruitment Process We will request a waiver of HIPAA authorization to allow us to conduct eligibility screening by evaluating medical records of outpatients seen in primary care and cardiology and of hospitalized inpatients to identify potentially eligible patients. We believe the waiver is justified because of the high percentage of heart failure patients who might not be eligible for this study. Potential patients will be approached in the hospital, given a brief overview of the study, and, if they are interested, will be asked to consent to screening. Research assistants will administer a screening questionnaire that includes some general "warm up" questions that don't affect eligibility, the AUDIT-C
39
, a substance abuse screening question, and the Kansas City Cardiomyopathy Questionnaire (KCCQ) 40 to potentially eligible patients. This strategy was approved by COMIRB and was successful in the nearly completed HF disease management trial (PCDM trial, COMIRB #07-0588; VA HSR&D CCN 06-068-3, Rumsfeld, PI, Bekelman, Co-I).
Approaching Potentially Eligible Patients 1. VA. We will contact potential research subjects to conduct eligibility screening using two methods: (1) Using a research database of veterans who consented to be contacted for future research studies as part of the VA PCDM trial (COMIRB #07-0588); (2) Using our clinical relationship with patients: VA inpatients (Dr. Robert Burke, Hospitalist Attending Physician); primary care patients (Dr. Connor McBryde, Primary Care Attending Physician); and cardiology patients (Dr. Brack Hattler, Cardiology Attending Physician). A research assistant will call (patients from the research database) or contact (via letter or approached in-person) potentially eligible patients identified through the medical record review with whom we have a clinical relationship and ask permission to describe the study verbally. contacted (via letter or approached in-person) who are (1) hospitalized with heart failure or (2) being seen in the outpatient cardiology clinic for heart failure, or (3) seen in internal or family medicine clinics who have heart failure. Patients at all three sites who are interested in the study will be asked to consent to screening [see recruitment scripts: patients contacted through our research relationship with them; patients contacted though our clinical relationship with them]. Patients who are eligible after screening will be asked to provide informed consent (CASA study and evaluation interview) and to complete HIPAA B forms. Informed consent will be conducted inperson, whenever possible. If geographic distance prohibits an in-person visit, the patient will be mailed the consent forms and a member of the study team will contact the patient via telephone to conduct the informed consent process. If amenable, the patient will sign the consent form and return it to the study team. Patients will be offered Three $25 gift certificates as incentives for participation, provided at the baseline, 6m and final study visits. Patients will be assigned a study identifier, a number unrelated to any personal identifying information. Data will be kept on a secured server (see Protocol Application for details). No surveys will be labeled with the subject's name or identifying information. The surveys will be coded with the patient's study identification number.
University of Colorado
Enrolled patients (n = 312) will be asked to "identify a family member or person who helps you the most with your medical condition, besides your health care provider" as part of the informed consent process. We will explain that part of this intervention is to involve informal (family) caregivers in care. Patients unable to identify an informal caregiver will not be excluded from the study. If the informal caregiver is not present with the patient, we will ask the patient for permission to contact the person they identified as a caregiver so that we may explain the study, address any questions and facilitate their participation. If the patient prefers, we will ask them to give this informal (family) caregiver a recruitment letter and/or our contact information so that they may contact us. When we establish contact with the informal caregiver, we will obtain verbal informed consent (see Attachment M, Request for Waiver of Caregiver Written Consent). Caregivers will be offered two $15 gift certificates as incentives for participation, provided at the baseline and final study visits.
Prior to the start of the study, all research staff will be trained and will practice the consent process. The training will include the process of fully explaining the study and consent procedures, explaining the possible risks and inconveniences, answering patient questions and assessment of the patient's understanding of the study and consent process.
Intervention personnel who participate in the focused group discussions will be asked to provide verbal consent at the beginning of all focus group. The consent will include:  Full disclosure that the session will be digitally recorded and detailed notes taken;  Statement that responses will be kept confidential and names will not be linked with responses in the summary;  An opportunity for them to excuse themselves Providers and leaders will be approached by phone, email, or in person (Aims 5 and 6). We will request a waiver of written consent for providers who participate in the interview (Aim 5) because the interviews may be done via telephone, are minimal risk, and it is impractical to obtain written consent from busy health care After the consent process, the study subject will keep a copy of the consent, and another copy will be maintained in separate locked file in a locked office of the study coordinator/research assistant.
Recruitment Targets
Aims 1-3: The estimated flow of patients and accrual goals are displayed in Figure 2 . These estimates are based on the investigators' prior experience recruiting similar HF patients, 28, 41 our Preliminary Studies, and account for readmission of the same patients. The accrual goals are displayed in Table 2 . Patients who refuse study participation will be asked why they refused, and if they consent, we will obtain their baseline demographic and clinical characteristics. The study coordinator will meet by conference call with the recruitment research assistants every week and with the study physicians once monthly until accrual goals are met for each site.
Aim 4: We anticipate at least 120 of the 150 (80%) eligible patients will participate, as they have already participated in the intervention and would be likely to offer feedback.
Aim 5:
We expect approximately 100 providers will complete the brief survey.
Aim 6: We expect to enroll 20 leaders and/or providers from rural sites in the VA Eastern Colorado Health Care System for interviews.
Randomization
During a recruitment period of two years, 312 patients (13/month x 24 months) will be randomized to receive either the intervention or usual care. Randomization will occur at the patient level. The random allocation sequence will be computer generated using block sizes of 2-4, an allocation ratio of 1:1, and stratification by recruitment hospital. The allocation sequence will be concealed until after the last subject has completed the 12-month follow up and all of the data have been entered, re-checked, and finalized. Diane Fairclough, DrPH, study statistician, will generate the allocation sequence and assign participants to the intervention and usual care groups.
Description of the Intervention and Control Groups Palliative symptom management and psychosocial care (PSMPC)
The intervention is patient-centered, multidisciplinary, addresses palliative care and psychosocial issues, and integrates with primary care provider (PCP) care. It is designed to support the emerging Patient Aligned Care A nurse (Registered Nurse, RN) and a social worker or psychologist (at least a Master's level, e.g., MSW or MA) will be the primary intervention personnel. The nurse will provide evidence-based palliative symptom management based on physician recommendations, and the social worker will provide psychosocial care that targets depression and adjustment to illness using an evidence-based, manualized psychotherapy supplemented with care for informal (family) caregivers. They will meet weekly for one hour with a collaborative care team (CCTeam) including a cardiologist (Dr.
Hattler, Co-I), palliative care specialist (Dr. Bekelman, PI), and primary care provider (Dr. McBryde, Co-I). The CCTeam will both provide care and write orders for treatments for PCPs to sign. This is exactly the same process as the VA HF clinical trial (COMIRB #07-0588).
Collaborative care: The CCTeam will provide evidenced-based symptom management [42] [43] [44] [45] [46] integrated with a HF care plan 47 based on the nurse and social worker interviews/evaluations of patients and medical record review within 1 week of enrollment. The nurse will record the Team's recommendations in a progress note in the patient's electronic medical record. The psychosocial care and other non-pharmacological recommendations will be implemented immediately by the social worker and nurse, respectively. Orders for medications or tests will be written for PCPs to review & sign at their discretion. The team will re-review patients if their symptoms are not improving based on monthly nurse phone calls or at a minimum of 1 and 2 months after enrollment.
Visits:
The nurse and social worker will make an initial in-hospital or clinic-based visit with patients. At the initial visit, a history and examination will be conducted and the patient will be asked to choose an initial symptom (fatigue, breathlessness, pain) on which to focus. Follow-up visits will be by phone, and the number and duration will be tracked. The nurse will provide approximately 4 visits (one phone call every 2-3 weeks) to check on symptoms, and the social worker will provide 6 visits approximately weekly to complete the psychosocial intervention. This will be allowed to vary dependent on patient needs.
Symptom Management:
To facilitate patient commitment and activation, we will suggest patients choose an initial symptom, pain, fatigue, or breathlessness, to work on. These symptoms are targeted because they are common, burdensome, and substantially affect quality of life in patients with HF. 6, 9 Patients will have the option of choosing other symptoms in subsequent visits (e.g., constipation). In our previous studies, the overwhelming majority seek help for one of these three symptoms or 31 , 33 which will be addressed through the psychosocial care. The nurse will conduct a nursing evaluation of the symptom and discuss management with the CCTeam. The CCTeam will implement evidenced-based management of the symptom, based on the Clinical Practice Guidelines for Quality Palliative Care. 63 Example evidence-based management for the evaluation and treatment of one of the symptoms, fatigue, is described in Tables 3 and 4 .
Psychosocial Care: The social worker will contact the patient, conduct a psychosocial assessment, 48 and offer 6 phone-based counseling sessions (outlined in Table 5 and detailed in counseling treatment manual and patient materials. This counseling was specifically developed and tested in patients with HF to improve depression. 49 The purpose is to help veterans adjust to living with HF and to activate/empower them to discuss issues related to their illness with their care providers. The social worker will also contact the patient's informal (family) caregiver to assess their needs and offer support in accordance with National Consensus Project for Quality Palliative Care 50 and National Association of Social Workers 48 guidelines. Dr. Turvey, co-investigator, will provide (1) a 2-day in-person training to the social worker or psychologist who will be conducting the counseling, (2) ongoing consultation and supervision through video-teleconferencing, and (3) review of audiorecordings of sessions to help with problems and to assure treatment integrity. The counseling will be supplemented with antidepressant medication if the collaborative care team agrees this is an appropriate, evidenced-based recommendation. 51 
Control Group (treatment as usual)
Patients in the control group will continue to receive care at the discretion of their providers, which may include referral to cardiology, palliative care, or mental health. They will also have the same amount of interaction with research assistants as the intervention patients, completing questionnaires and participating in study visits at the same frequency. Patients' providers will be given the results of all baseline data surveys, and patients will be given an information sheet that outlines self-care for HF. For example, patients in the usual care arm who have significant depressive symptoms will be notified of this and their providers will also be contacted. Referring providers will then assume responsibility for depression care at their discretion, with no constraints on treatment or referrals. Therefore, the usual care patients may benefit from the feedback of screening instruments to their referring providers. This sets a high but appropriate standard by which to judge the effectiveness of the intervention. Budgetary constraints prohibit giving usual care patients additional time with a nurse or social worker to match the intervention patients' time. If the intervention is successful, we will plan for this in a subsequent study.
Study Procedures for Positive Depression Screening
The Patient Health Questionnaire-9 will be used to evaluate depression symptoms (see page 11). For study participants who have a positive screen for depression (a score equal to or over 10 on the PHQ survey), a research note documenting this will be entered into the electronic medical record and the PCP will be notified as a co-signer on this note. If a study participant scores greater to or equal to 1 on question 9 of the PHQ, which asks about thoughts of dying or self-harm, three procedures will occur: (1) the PCP will be contacted through an electronic medical record note; (2) the PI will be notified; and (2) the CCTeam nurse or social worker or psychologist will ask the participant to discuss their response to this question. If the study participant expresses active suicidal thoughts and is felt to be at imminent risk, the study participant will be transferred the patient to the emergency or mental health department. Data Collection, Measures, and Analysis Data will be collected and analyzed to assess the intervention effects on patients (Aim 1), conduct the mediation analysis (Aim 2), the intervention effects on informal caregivers (Aim 3),evaluate intervention content and process (Aims 4-5) and determine interest in program and implementation capacity of rural providers (Aim 6) utilizing the following methods.
Patient Outcome Measures and Planned Study Visits (Aims 1-4)
Research assistants will administer measures to patients during four study visits: enrollment (baseline), 3. 6, and 12 months ( Table 6 ). The estimated completion time is 45-50 minutes with an additional 15 minutes for intervention patients who complete the evaluative interview. The measures were chosen to reflect domains of the conceptual model ( Figure 1 ) as follows (instrument abbreviations defined below): 38, 40, 72 The single depression item will be removed from analysis of the quality of life subscale given measurement overlap with the PHQ-9.
MSAS-SF:
The Memorial Symptom Assessment Scale is a valid and reliable self-report measure of symptom distress. 63 Patients check off which of 10 symptoms (e.g., pain) they have had over the past week. Patients who have had the symptom rate how much that symptom distressed or bothered them from 0 ("not at all") to 4 ("very much") on a numeric rating scale. The primary endpoint will be the sum of the three symptoms the trial is targeting (pain, lack of energy, and shortness of breath) and a secondary endpoint will be the sum of the other symptoms, because the intervention will most likely affect them but they are not directly targeted. This is also because improvements in one symptom could lead to improvements in other symptoms as a result of symptom clustering. [64] [65] [66] 3. PHQ-9: The Patient Health Questionnaire-9 is a 10-item valid and reliable instrument that provides a continuous measure of depressive symptoms and is 88% sensitive and specific for a diagnosis of major depressive disorder (administration time 3 minutes). 67, 68 The PHQ-9 was developed in medically-ill outpatients, including patients with HF. 4 . GSDS: The General Symptom Distress Scale includes a measure of overall symptom distress that is reliable and valid 69 and asks, "In general, how distressing are all of your symptoms to you?" and is rated on 0 ("not at all distressing") to 10 ("extremely distressing") on a numeric rating scale. Patients rank the symptoms into the first, second, and third most distressing, and also rate how well they can manage those symptoms.
PEG:
The PEG is a reliable and valid 3-item scale of pain intensity and interference. 70 Patients rate the pain's intensity and interferences with their enjoyment of life and general activity on a numeric rating scale ranging from 0 ("no pain" or "does not interfere") to 10 ("pain as bad as you can imagine" or "completely interferes").
PROMIS Fatigue: The Patient Reported Outcomes Measurement Information System (PROMIS) Fatigue
Scale is an 8-item scale that measures fatigue impact and fatigue experience. 71 Patients rate how much fatigue they have experienced and how much fatigue has bothered them on a 5-point Likert-type scale ranging from 0 ("not at all") to 5 ("very much").
Dyspnea Assessment:
The Dyspnea Assessment is a 3-item measure that asks patients to rate the intensity of their shortness of breath over the past week and how that interferes with their day-to-day activities and enjoyment of life. Two of these questions are items from the validated Pulmonary Functional Status and Dyspnea Questionnaire (PFSDQ-M) 72 and the third item was adapted from the PEG. 70 8. SCHFI: The Self-care of Heart Failure Index is a valid and reliable 22-item self-report measure (administration time, 8-10 minutes) of self-care that includes three self-care scales: maintenance, management, and confidence. 73 9. FACIT-Sp: The Functional Assessment of Chronic Illness Therapy -Spiritual well-being scale (12 items; admin time 5 minutes) is a self-report measure that assesses overall spiritual well-being and includes subscales of meaning/peace and faith. It was developed and validated in a large sample of medically ill patients, many of whom had cancer, 74 and has good psychometric characteristics in HF patients. 27 10. QUAL-E: The Quality of Life at the End of Life is a valid and reliable self-report measure of several domains, each scored separately, of quality of life in advanced illness. 75 We will use the relationship with health care system, preparation, life completion, and global quality of life sub-scales (16 items total, administration time 8-10 minutes).
TICS:
The Telephone Interview for Cognitive Status is an 11-item verbally administered test of cognitive status. The TICS takes approximately 4 minutes to administer and assesses memory and other cognitive functions. The TICS was originally developed to discriminate between cognitive normals and dementia patients 76 and has demonstrated good sensitivity and specificity when discriminating between normals and individuals with mild cognitive impairment. 76 The TICS will be used as a covariate in the analyses.
12. Control Preferences Scale: The Control Preferences scale is a one-item measure of patient preferences regarding participation in health-care decisions. Using a 5-point Likert-type scale ranging from patient-only decision-making to provider-only decision-making, patients rate the extent to which they want to be involved in their care. 13. GAD-7: The Generalized Anxiety Disorder-7 is an 8-item valid and reliable screening instrument for four common anxiety disorders in primary care (post-traumatic stress disorder, generalized anxiety disorder, panic disorder, and social anxiety disorder. 79, 80 It provides a continuous measure of anxiety symptoms.
14. Mutuality Scale: The Mutuality Scale of the Family Caregiving Inventory is a 15-item scale (5 minute administration) that assesses the extent to which a relationship is characterized by emotional investment and the individual feels as if the relationship is gratifying and mutually supportive. Evidence suggests the Mutuality Scale is reliable and valid measure of relationship quality. 81 15. EQ-5D-5L: The EQ-5D-5L is a measure of health status in terms of 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Patients rate these dimensions on 5-point scales ranging from no problems to extreme problems. A sixth item assesses how good patients think their health is today from 0 ("worst health you can imagine") to 100 ("best health you can imagine"). 82 16. Satisfaction with Healthcare: Patients will rate their Satisfaction with their Healthcare using three items that ask how satisfied they are with the care they have received for their heart failure, symptoms, and dealing with stress, depression, or mood problems. Patients will rate their satisfaction using a 7-point scale ranging from 1 ("very dissatisfied") to 7 ("very satisfied"). Similar questions have been used in effectiveness trials of collaborative care. 83 17. Sheehan Disability Scale: The Sheehan Disability Scale is a 5-item measure of functional disability in work, social, and family life. Patients rate how much their symptoms have disrupted their lives on an 11-point scale ranging 0 ("not at all") to 10 ("extremely"). This measure has been shown to be a valid and reliable measure of disability that is sensitive to treatment effects in a variety of outcome studies. 84 18. Demographics/Study Form: Age, gender, race and ethnicity, education level, and clinical variables will be determined at the enrollment visit from the electronic medical record and patient self-report. NYHA classification, etiology of HF, most recent ejection fraction, and BNP or NT-pro BNP will be documented. Medical history (including comorbidities), current medications, and number/reasons for hospitalizations in the previous two years will also be collected at the enrollment visit. At the final study visit, patients will be asked to relate interim events at follow-up visits, including hospitalizations with cause and emergency department (ED) visits, the reasons for them, and for permission to obtain medical records relevant to such events. Medications will be documented again.
19. Interim events: Over the 12-month study period for each patient, the following events will be assessed through medical record review to supplement patient report: hospitalization (with cause), outpatient/ED visits, and mortality. Vital status will also be ascertained via the VA Vital Status File and the National Death Index.
Program Evaluation:
Participants in the intervention group will be asked for their feedback regarding the helpfulness of the intervention portion of the study after all of the outcome measures have been completed.
Process measurement
We will document study processes to facilitate replication and incorporation in dissemination manuals if the intervention is successful and to provide insights for future interventions if not successful. Process measurement will also generate insight into which aspects of the intervention were most effective, and will allow accounting intervention resource use. Process measurement will include: (1) tracking of nurse and social worker contacts with patients, including number, time spent, and reason; (2) tracking of adherence to the intervention protocol using a study form that examines whether or not study protocol actions were completed, as measured by medical record review; and (2) accounting of medication and testing recommendations by the collaborative care team and proportion executed.
ZBI-SF:
The Zarit Burden Inventory-Short Form (ZBI-SF) is a 12-item measure of the extent to which caregivers feel overwhelmed by their caregiving responsibilities. The ZBI-SF takes approximately 4 minutes to administer and has been shown to be a reliable and valid measure of subjective caregiver burden. 87 5. DOBI: The Dutch Objective Burden Inventory (DOBI) measures the number and frequency of caregiving tasks the caregiver performed over the past three months. The scale includes 38 tasks and takes approximately 8-10 minutes to administer. The scale has been validated for use in heart failure caregivers and has good evidence for reliability and validity. 88 6. PHQ-8: The Patient Health Questionnaire-8 is a form of the PHQ-9 (described above) that does not ask about thoughts of death or suicide. It is recommended to use this version of the PHQ when assessing from a distance and when the goal is to assess relationships among variables rather than to screen for depression. 85 7. CC-SCHFI: The Caregiver Contributions to The Self-care of Heart Failure Index is a valid and reliable 22-item self-report measure (administration time, 8-10 minutes) of caregivers' contributions to patient self-care that includes three self-care scales: maintenance, management, and confidence. 89 8. Mutuality Scale: Same as above.
9. ESSI: The ENRICHD Social Support Inventory (ESSI) measures social support. This 7-item scale takes approximately 3 minutes to complete and assesses the extent to which an individual has sources of structural (e.g., a partner), instrumental (tangible), and emotional (caring) support. This measure was developed for use in a population with cardiovascular disease and has demonstrated good reliability and validity. Data collection and management (Aims 1-3) To ensure data integrity, the study protocol manual will include a section on data collection with descriptions of each data element or measure and instructions for its accurate collection or acceptable source. Several strategies will be used to avoid missing data and dropout, such as follow-up phone calls and letters. The study will use REDCap, a secure, HIPAA compliant, web-based application for building and managing online databases which is provided free of charge by the UCD CCTSI. All patients who are screened will be entered into one REDCap database that will store names, last four SSN (VA only) or medical record number (UCH and DH), eligibility and screening data, and contact information (phone numbers and addresses). There they will be assigned a study ID number that will link their information to the rest of their responses if they enroll in the study. A second REDCap database will contain patient and caregiver survey data and patient medical information. This database will not have any personal identifying information and will only be linked by study ID number. A third clinical database will be created in Microsoft Access that will be stored on secure VA servers with limited access. Only patients randomized to the intervention will be entered into this database, and it will store medical and visit data to track the process of the intervention. The data analyst will construct the study databases.
Monitoring plan Monitoring will focus on recruitment, baseline comparability of treatment groups, protocol adherence, completeness of data, accrual of primary endpoint data, safety, and follow-up rates. This monitoring will provide the basis for reporting to a DSMB and quarterly review by the study investigators. Please refer to table 9 for a summary of data collection and analyses for Aims 4-6. 
Interviews of Primary Care Providers:
We will administer a brief interview to select primary care providers who have patients who have completed the CASA intervention. Using a combination of rating scales and a few open-ended questions, the goal of these interviews is to efficiently identify strong positive or negative opinions about the usefulness of different CASA components, integration of CASA into work flow, and CASA's impact on quality of care. We will also ask for their insights into ways to sustain and spread CASA to other urban and rural sites.
Focused Group Discussion with Intervention Team Members:
We will conduct several (2-3) structured group discussions with intervention team members to debrief about CASA implementation. The goal of these feedback sessions is to elicit intervention team views about what is and is not working well; what parts of CASA could be streamlined, dropped or enhanced; their views about patient, family caregiver, and primary care provider receptivity and responsiveness. Finally, we will ask team members about what it would take to scale-up and sustain a program like CASA as a regular service for patients with CHF within the current site and in rural sites and what should be included in an implementation toolkit. Dr. Main will lead these focused group discussions which will be audiotaped and transcribed.
Rural feasibility data collection (Aim 6)
Site Visits and Interviews with Rural Health System Leaders and Providers: Drs. Bekelman and Main will conduct site visits at rural clinics to explore their capacity to adapt, implement and sustain CASA. During the site visits, we will tour facilities and interview approximately four key leaders and providers at participating sites who have a role in decision making and planning for CASA implementation. Leaders and providers will be identified by key personnel at existing sites. Interview guides will use a combination of broad, open-ended questions to elicit leader/provider perceptions of CASA, using questions/probes guided by CFIR constructs. The questions are designed to improve our understanding of the facilitators and barriers to scaling up use of the CASA in rural areas, learning about their infrastructure and resources, current arrangements for palliative and psychosocial care, and how the CASA care model could be organized and implemented to improve quality of CHF care. We will learn how CASA fits within their organizational mission and priorities, meets a clear patient need, and might help them improve the quality of patient care. We will identify preferences around implementation processes to inform an implementation strategy. These interviews will be audiotaped and transcribed.
Data Analysis Plan
Aim 1: Assess the effect of a symptom management and psychosocial care intervention on heart failurespecific health status, measured by the KCCQ overall score, as a primary endpoint, and symptom distress, depression, quality of life, self-care, and spiritual well-being as pre-specified secondary endpoints.
Descriptive Statistics and Basic Comparisons
All analysis variables, both predictors and outcomes, will be examined carefully prior to any formal statistical analysis. Standard graphical methods, including histograms and boxplots, will be used to examine overall distributions and identify potential outliers, which will be confirmed prior to inclusion in analysis. Internal consistency of multi-item scales will be examined, and whenever possible, items and scales will be compared to existing data to ensure appropriate performance within our HF population. Data transformations will be considered if indicated, such as log transformations for highly skewed data, to meet model assumptions. Each measure will be summarized using standard descriptive statistics, including means and standard deviations, medians, and ranges for continuous measures and proportions for categorical measures. Baseline characteristics will be compared between groups using appropriate exact nonparametric tests, such as Fisher's exact tests and Wilcoxon rank-sum tests.
Primary Analysis Data from all participants will be included regardless of level of participation using an intent-to-treat approach.
All outcome measures will be analyzed as continuous variables. Analyses of the repeated measures, including primary and secondary endpoints, will be performed using maximum likelihood estimation (MLE) for incomplete data (SAS Proc Mixed). This approach has several advantages: 1) all available data on eligible subjects can be included in the analysis even when there are missing data at follow-up, 2) MLE estimates the correlation between related measures and adjusts test statistics appropriately, 3) time varying covariates can be incorporated into the model, and 4) the assumptions about missing data are relaxed from Missing Completely at Random (MCAR) to Missing at Random (MAR). 91 The primary analyses will not explicitly consider the prerandomization variables unless there is a strong imbalance across the two groups, but the effect of these variables on outcome will be investigated as secondary analyses. Because missing data may occur as a result of morbidity or mortality, we will also perform sensitivity analyses utilizing auxiliary information such as BNP, hospitalization (with cause), outpatient/ED visits, and mortality to convert the missing data problem to a setting that is more likely to be MAR conditional on the auxiliary information.
Additional Exploratory Analyses
We also propose several exploratory analyses that will investigate how relationships between the symptom experience, depression, and health-related quality of life change over time. These analyses will guide subsequent applications of our intervention. For example, an understanding of the time course by which symptoms and depression effect quality of life will help target assessments and treatments focused on quality of life outcomes to this time frame. The exploratory analyses will address two questions: Question 1: How much do changes in potentially modifiable factors, such as symptom severity and burden and depression, explain variation in quality of life? We hypothesize that changes in modifiable factors over time explain the largest amount of variance in quality of life over time. The analysis (SAS Proc Mixed) will utilize the change from baseline in quality of life (as measured by the KCCQ quality of life subscale) at 3, 6 and 12 months as the outcome. We will estimate the proportion of the variance explained by baseline demographic variables (e.g. age, gender); baseline measures of disease severity (e.g. ejection fraction, BNP); and changes in modifiable factors (symptom distress and severity, depression, attitudes about impairment and spiritual wellbeing).
Question 2: How does the strength of the association between changes in quality of life and changes in the modifiable and unmodifiable factors vary over time? We hypothesize that the modifiable (particularly the psychological) associations will increase and the unmodifiable will decrease over time. These hypotheses will be tested by adding interactions with time to the models employed to answer question 1.
Aim 2. Evaluate whether the intervention influences quality of life indirectly through effects on symptom severity and depression. This aim will examine our conceptual model using a mediation analysis. The data gathered in the clinical trial described in Aim 1 will be used to complete this aim.
Overview Previous observational studies demonstrate aspects of the conceptual model 19 (Figure 1 ), but no intervention studies have examined these relationships. The objective of this aim is to understand longitudinal relationships between symptoms, depression, and quality of life. We are not powered to examine direct intervention effects 92 we are adequately powered to examine mediational pathways by which the intervention influences quality of life (see "power analysis" below). We will test the hypothesis that symptom experience, measured as symptom severity using the ESAS total score, and the number of depressive symptoms, measured by the PHQ-9 score, mediate the relationship between the intervention and health-related quality of life, measured by the KCCQ quality of life subscale. This hypothesis will be tested using a structural equation modeling framework because the variables are measured longitudinally, and we are interested in testing mediation pathways and using multiple dependent variables. The rationale for this aim is that a fundamental understanding of the relationships between symptoms, depression, and quality of life is critical to the further refinement of therapeutic strategies to improve symptoms and quality of life. For example, we will understand the relative importance of each path of intervention effect, and consider strengthening or diminishing the palliative symptom management or psychosocial care components. If the intervention is not successful, a deeper understanding of the relationships between these variables will guide the content of future interventions to improve symptoms and quality of life. Furthermore, examining these variables in a longitudinal study will provide much stronger evidence for their relationships.
Data Analysis Plan
The analyses for this aim will be carried out using Mplus 93 following well-established statistical methods for testing the mediated effect with longitudinal data 94 and multiple mediators. 95 The general structure of the proposed model is depicted in Figure 3 . This model is a simplified version of the overall conceptual model (Figure 1) . The model will be estimated in a parallel process growth modeling framework where the change in symptom severity over time will be estimated simultaneously with the change in the number of depression symptoms over time, each of which will be captured by latent initial status and slope factors. The a1 path from the intervention to symptom severity will measure the impact of the intervention on changes in symptom severity (the symptom severity slope factor) and the a2 path will test the impact of the intervention on changes in the number of depression symptoms (the depression slope factor). The b1 path from depression to symptom severity is included to test the hypothesis that some of the impact of depression on quality of life will occur through reduced symptom severity. The b2 and b3 paths capture the effects of the symptom severity and depression slope factors on health-related quality of life measured at the end of the study. The overall fit of the proposed model, the significance of the individual paths, and the significance of the mediated effects will be assessed. The mediated effects will be calculated using the product of coefficients method and will be evaluated for statistical significance by a bias-corrected bootstrapped standard error estimate. 96 Three specific indirect effects will be estimated: (1) the indirect effect of the intervention on health-related quality of life through symptom severity (a1*b2), (2) the indirect effect on quality of life through depression (a2*b3), and (3) the indirect effect on health-related quality of life in a multiple mediator framework through the intervention's impact on depression and the impact of depression on symptom severity (a2*b1*b2).
Through exploratory analyses, we will examine the same model using our alternative measures of the symptom experience (symptom distress, GSDS) and health-related quality of life (QUAL-E subscales).
Aim 2 Power Analysis
Power calculations were based on the magnitude of the individual paths, as well as the power to test each of the three proposed specific indirect effects. Power was calculated in Mplus using a Monte Carlo simulation. 98 The population model followed the structure of Figure 3 , but was estimated as a parallel process growth model. For consistency with the power estimates under Aim 1, moderate-sized effects from the intervention to symptom severity and depression were specified (i.e., 13% of the variance in symptom severity and depression accounted for by the intervention). Based on an earlier cross-sectional study showing large correlations (>.50) between symptoms, depression, and quality of life, 6 large effects (26% of the variance in outcomes) were specified for the paths from depression to symptom severity, from depression to health-related quality of life, and from symptom severity to quality of life. Assuming a two-sided = .05, power was sufficient (>=.80) to detect significant differences in each of the paths and in the three mediated effects. Power estimates may be considered conservative because Monte Carlo simulations do not calculate power using bootstrapped estimates, although this method has been shown to be the most powerful method for testing the significance of the mediated effect 99 and will be used in this analysis.
Similar to Aim 1, analyses of the repeated measures will be performed using maximum likelihood estimation (MLE) for incomplete data (SAS Proc Mixed) to examine the differences between caregivers of patients in the intervention compared to caregivers of patients in the control group over time on caregivers' depression, burden, benefit-finding, perceptions of patients' symptoms, quality of the caregiver-patient relationship, and contributions to patients' heart failure self-care.
Data Analysis for Aims 4-6
The qualitative data collection and analysis is designed to be flexible and iterative in nature. Using the Consolidated Framework for Implementation Science (CFIR), we will analyze project data to address each specific aim, then conduct a final, more comprehensive analysis to examine differences and similarities of CFIR and other implementation influences that emerge within the current implementation context (Denver Metro Area health care systems) compared to the planned implementation contexts (rural health systems). This approach is informed by the CFIR, which reinforces the importance of understanding implementation barriers and facilitators within the context that an intervention or innovation is planned, implemented, and sustained. By focusing our analysis within each implementation context -current and planned -we are able to describe and disentangle the importance of these different contexts and their influence on perceived facilitators and barriers of CASA implementation and scale-up.
Using a combination of inductive and deductive methods, we will create an evolving set of codes linked to units of text (fragments, sentences or paragraphs) using the Atlas.ti software package. Dr. Main and the research assistant will serve as primary coders for qualitative data, and Dr. Bekelman will review coding and codebooks as they are developed. We will follow a systematic process to enhance coder agreement in assigning codes and a peer debriefing process that requires regular meetings with Drs. Main, Bekelman, and the research assistant to review and refine codes, code definitions and conceptual boundaries for our analysis. 43, 44 The iterative analysis will begin by using the a-priori codes based on intervention content and structures and questions used for data collection, with continual refinement of codes and adding new codes as new insights emerge. Through systematic coding we will quickly develop working themes and hypotheses that will be examined (and inform any minor changes in data collection interview/survey guides). We will both audiotape and take detailed notes during all data analysis meetings in order to document proposed codes and code revisions, proposed themes and their descriptions, and other decisions made during these working meetings. Although we will primarily analyze qualitative data for Aim 5 and Aim 6 separately, our data collection methods and analytic approaches are designed so we can apply an overlapping set of CFIR constructs as a-priori codes for addressing both study aims. Using overlapping CFIR codes will both allow us to develop contextually grounded understandings of CASA implementation and sustainability and explore important similarities and differences within and across settings. For the proposed evaluation, our analysis will focus on those selected CFIR constructs related to provider and organizational influences on CASA implementation and sustainability, including factors related to organizational context itself. Specifically, we will use codes reflecting the CFIR domain of "Inner Setting" to help us understand organizational context with which CASA is or will be implemented, and a-priori codes for the "Outer Setting," which will help us understand more about, for example, different patient and resource needs and health system expectations and pressures that influence implementing a team-based palliative care intervention like CASA in urban and rural environments. For the analysis of rural interviews, we are particularly interested in understanding the Inner Setting construct of Readiness for Implementation. Understanding this construct will help us describe organizational capacity, resources, and infrastructure that will influence decisions about CASA implementation and sustainability.
Using a combination of inductive and deductive methods, we will create an evolving set of codes linked to units of text (fragments, sentences or paragraphs). This iterative analysis will begin by using the a-priori CFIR constructs as codes, with continual refinement of codes and adding new codes as new insights emerge. Through systematic coding and rating of constructs as either a positive (facilitator) or negative (barrier) influence, we will quickly develop working themes that will be examined within each aim. We will both audiotape and take detailed notes during all data analysis meetings in order to document proposed codes and code revisions, proposed themes and their descriptions, and other decisions made during these detailed working meetings. We will use several recommended strategies to enhance the validity or credibility of qualitative findings: [45] [46] [47] (1) structured interview guides administered by well-trained interviewers, (2) coding templates and detailed descriptions of codes, coding decisions and analysis strategies to document all phases of the data analysis (audit trail); and (3) team approaches (at least two analysts) to develop coding templates and independently code subsets of transcripts/notes to determine their agreement and application of codes and code definitions.
Sample Size
Aims 1-3 We plan to accrue 312 patients and anticipate 15% of the participants will die due to progression of their HF and an additional 10% will dropout due to miscellaneous reasons. Thus, approximately 117 participants per arm will have all four assessments. With this sample size, we have 86% power to detect a moderate effect of 0.4 SD (two-sided test, alpha=0.05). This corresponds to a change in KCCQ score of 6-8, depending on the standard deviation in our sample (prior standard deviations of the KCCQ overall score range from [15] [16] [17] [18] [19] [20] . A change is KCCQ score of 6-8 is above the clinically meaningful change in KCCQ score.
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Aims 4-6
The sample sizes are described in Table 9 .
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Limitations and Considerations
1.
Given the multi-faceted intervention, it will be unclear which components are essential. The intervention was specifically designed to have multiple components because symptoms and quality of life are complex phenomena. Multicomponent care interventions need to be tested as a whole. The quality improvement literature is rife with evidence that unimodal interventions have a low likelihood of success and interventions that have been shown to be effective in some studies usually have modest effects unless they are combined. 100, 101 The analyses in Aim 2 will contribute to understanding the relative importance of intervention components.
If the intervention is not successful in showing improvements
in any of the outcome measures, this will be an important, if undesired result, but study will still contribute to the evidence base regarding models of palliative care delivery and specifically HF palliative care. The process monitoring will inform future interventions.
What is the potential for contamination?
It is possible that a provider may have patients in both the intervention and control arms. However, this is unlikely to have a significant effect because: a) these patients will represent a very small percentage of the patient panels of a given provider; b) providers will not know whether care recommended for a given intervention patient would be appropriate for a given control patient; and c) there is no clear evidence that specific recommendations for a given patient by a specialist or collaborative team are carried over to other patients by providers; and d) changing provider behavior is notoriously difficult. If any contamination did take place, it would bias results toward the null and would not invalidate any differences detected in outcomes.
4. Recruitment problems. The recruitment goals are modest and reasonable for each site. If necessary, resources can be diverted to increase efforts at one of the recruitment sites. We can also add recruitment of outpatients using the same enrollment criteria and conduct a sensitivity analysis to evaluate if outcomes are different for those recruited in this setting.
5.
Informal caregiver outcomes are not measured. This is a patient-focused intervention; caregiver issues are not the primary focus. Prior work has shown the importance of caregivers in HF care, and caregiver involvement is part of quality palliative care. However, caregiver outcomes are beyond the scope of this study. 6 . Key palliative care elements, such as spiritual care, are not explicitly mentioned. The palliative care specialist is on the team to bring all aspects of palliative care to patient care. If spiritual distress is identified, for example, the team can enlist a chaplain's assistance. The role of spiritual well-being in quality of life will be examined in Aim 3 and the intervention can be modified to formally include spiritual care if necessary.
7. Even if the intervention is not successful, we will still be able to conduct analyses examining the proposed relationships among depression, symptoms, and quality of life, and these analyses will inform the focus of future interventions designed to improve quality of life. In fact, if intervention and control patients are combined in the analysis, we will have adequate power to include functional status in the model in order to make inferences about relationships between symptom distress/severity, depression, and functional status. 8 . If the correlations assumed in the power calculation are too high and the analysis is underpowered, the model will still be useful for examining the hypothesized relationships among variables. We would still examine the magnitude and significance of the individual paths, but perhaps not expect that the indirect effects will be significant. 
Knowledge to be gained and Future Directions
Collectively, the proposed studies will impact clinical care for patients with HF by testing an innovative, evidence-based, theory-driven palliative symptom management and psychosocial care intervention and informing continued development of targeted interventions to improve outcomes. The core components of the intervention are structured to ease replication, implementation, and dissemination, and we plan subsequent studies to conduct an economic analysis of the intervention and to determine if the intervention has an effect on health care utilization and survival. The mediation analyses will inform subsequent interventions by identifying strengths and weaknesses of the proposed intervention. This study will contribute to a key gap in HF and palliative care research. If the intervention is successful, we plan future studies to conduct an economic analysis of the intervention and to determine if the intervention has an effect on utilization (outpatient and emergency department visits and hospitalizations) and survival. Because symptoms and depression are associated with utilization and survival, we will use the data collected on this study to estimate the sample size required to detect intervention effects on these outcomes. The analyses from Aims 2 and 3 will inform a decision to modify the content of the intervention in subsequent studies. If the intervention in this study improves outcomes, we will plan a larger and more rigorous study in diverse geographic locations using a control group that has the same contact time with the nurse and social worker, but that includes HF education or general support rather than palliative symptom management and structured psychosocial care. Ultimately, if the intervention is successful, we would focus on implementation and dissemination, in part using our immediately-available networks. Furthermore, the intervention could be adapted and studied in patients with other chronic illnesses, such as COPD, increasing its potential significance and utility. Similar to patients with HF, patients with COPD have many burdensome symptoms, comorbid depression, and poor quality of life. Finally, if the intervention is not successful, the process monitoring and the analyses in Aims 2 and 3 will guide our efforts in subsequent intervention modification and testing.
By understanding patient, provider, and organizational issues involved in implementation and sustainability, this proposed research will inform how to make available a team-based program to help address these problems and improve quality of life for the many veterans living with CHF. The research will help expand the reach of this program so it can impact a wide range of veterans, including veterans in rural areas.
Timeline
The proposed projects will be completed within a 5-year timeline (Table 10 ). The table illustrates timing for completion of the main study tasks using 6-month increments during the 5-year timeline. 
